Regeneron Pharmaceuticals Inc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $30.16. The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Direxion Daily 20 Year Treasury Bull 3X Shares pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| REGN | TMF | |
|---|---|---|
Market Cap | $83.43B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $852.03 | $44.14 |
52-Week Low | $555.51 | $29.83 |
Enterprise Value | $78.14B | — |
Dividend Yield | 0.46% | — |
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
TMF, a leveraged ETF tracking long-term Treasury bonds, trades at $30.85, down 0.13% for the day, with a bearish technical signal driven by moving averages. The stock faces significant long-term erosion, as highlighted by a recent article showing a $10,000 investment five years ago would now be worth about $1,527. Key support lies at $30, with resistance at $31.
The outlook remains challenged by interest rate sensitivity and leverage decay, posing risks for investors seeking Treasury exposure. Opportunities may arise from potential Federal Reserve policy shifts, but volatility and structural ETF risks demand caution.
Trailing returns across standard periods
Latest headlines on both assets
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →